Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024 16:11 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Nasdaq Announces Launch of Secondary Offering of Nasdaq Common Stock
July 26, 2024 16:10 ET
|
Nasdaq, Inc.
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) (the “Company” or “Nasdaq”) today announced a secondary public offering of 41,604,207 shares of its common stock currently...
Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements
July 26, 2024 16:10 ET
|
Rail Vision Ltd.
Ra’anana, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (the “Company”) (Nasdaq: RVSN), a technology company at the forefront of revolutionizing railway safety and the data-related...
Cheetah Net Supply Chain Service Inc. Announces Closing of $1.49 Million Follow-on Public Offering
July 26, 2024 16:10 ET
|
Cheetah Net Supply Chain Services Inc
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Cheetah Net Supply Chain Service Inc. (“Cheetah Net” or the “Company”) (NASDAQ: CTNT), a provider of warehousing and logistics services,...
Hudson Acquisition I Corp. Announces Receipt of Nasdaq Delisting Notice, Submission of a Hearing Request and Initiation of Compliance Measures
July 26, 2024 16:05 ET
|
Hudson Acquisition I Corp.
NEW YORK, NY, July 26, 2024 (GLOBE NEWSWIRE) -- Hudson Acquisition I Corp. (the "Company" or "HUDA") (Nasdaq: HUDA) today announced that it received a delisting notification letter (the “Notice”)...
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
July 26, 2024 16:05 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead...
Vivid Seats to Participate in Canaccord Genuity’s 2024 Growth Conference
July 26, 2024 16:05 ET
|
Vivid Seats LLC
CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands...
Credit Acceptance Announces Timing of Second Quarter 2024 Results and Webcast
July 26, 2024 16:02 ET
|
Credit Acceptance Corporation
Southfield, Michigan , July 26, 2024 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that...
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
July 26, 2024 16:01 ET
|
NewAmsterdam Pharma N.V.
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
Silvercrest Asset Management (SAMG) to Announce Second Quarter 2024 Results and Host Investor Conference Call
July 26, 2024 16:01 ET
|
Silvercrest Asset Management Group Inc.
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on August 2, 2024, to discuss...